SBIR/STTR Research Award
Development of a VesiVax HIV Vaccine Formulation
Award amount
$1,994,571Program and phase
SBIR · Phase IIAward year
2022Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- MOLECULAR EXPRESS, INC
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- R1JMHFESEKD5
- Solicitation number
- PHS-2021-1
- Topic code
- 89
Research abstract
Particle-based Co-delivery of HIV immunogens as Next-generation HIV Vaccines: Tailored immunogens (such as Envs, monomers, native and/or native-like trimers, nucleic acids/RNA such as mRNAs, self-amplifying RNAs) combined with an effective multivalent antigenic display on nanoparticles for delivery may provide a strategy to promote strong and long-lived neutralizing antibody responses against HIV and direct affinity maturation toward HIV neutralizing antibodies. The objective of this contract is to evaluate the different co-delivery methods of a model HIV antigen using the VesiVax liposomal platform.
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Preclinical Development of a ME-1001, a Synthetic Lung Surfactant
- DESIGN AND ENGINEERING OF VESIVAX HIV IMMUNOGEN FORMULATIONS
- Development of a VesiVax TLR7 Formula as an Effective Adjuvant
- DEVELOPMENT OF VESIVAX CO-ADJUVANT FORMULATION OF 2E151.
- VesiVax Vaccine Formulation Against Neisseria gonorrhoeae
Research funding history
55 SBIR/STTR records share this UEI (1998–2024). Reported award amounts total $36,762,517. Reported amounts are not federal obligations.
Phases: Phase I, Phase II, Phase II – Direct to Phase II
Agencies: Department of Health and Human Services, Department of Defense